Use of adenovirus vectors expressing Epstein-Barr virus (EBV) immediate-early protein BZLF1 or BRLF1 to treat EBV-positive tumors.

@article{Feng2002UseOA,
  title={Use of adenovirus vectors expressing Epstein-Barr virus (EBV) immediate-early protein BZLF1 or BRLF1 to treat EBV-positive tumors.},
  author={Wen-hai Feng and Eva Maria Westphal and Amy Mauser and Nancy Raab-Traub and Margaret L Gulley and Pierre Busson and Shannon C. Kenney},
  journal={Journal of virology},
  year={2002},
  volume={76 21},
  pages={10951-9}
}
The Epstein-Barr virus (EBV) genome is present in a variety of tumor types, including virtually all undifferentiated nasopharyngeal carcinomas (NPC) and a portion of gastric carcinomas. The uniform presence of the EBV genome in certain tumors (versus only a very small number of normal B cells) suggests that novel therapies which specifically target EBV-positive cells for destruction might be effective for treating such tumors. Although the great majority of EBV-positive tumor cells are infected… CONTINUE READING